gdc

Web Exclusives

Predicting Which Patients with Chronic Lymphocytic Leukemia Might Need Early Treatment
CLL Monthly MinutesLeukemia
A new laboratory-based scoring system may allow physicians to better predict which patients with early-stage CLL are most likely to require early treatment.
Evaluating the Risk of Severe COVID-19 in Patients with Chronic Lymphocytic Leukemia
CLL Monthly MinutesLeukemia
Patients with CLL may be at increased risk for developing severe COVID-19. Experts have provided insights on how to protect them while still delivering optimal care.
Zanubrutinib Now Recommended for Certain Patients with Chronic Lymphocytic Leukemia
CLL Monthly MinutesLeukemia
Updated National Comprehensive Cancer Network (NCCN) guidelines now recommend zanubrutinib as alternative first- and second-line therapy for some patients.
A Look at Cannabis Extracts for Patients with Chronic Lymphocytic Leukemia
CLL Monthly MinutesLeukemia
Cannabis compounds such as cannabidiol have shown cancer-fighting activity in the lab. What should patients know?
Disparities in the Treatment and Care of Minority Patients with Cancer
Racial Disparities
April is National Minority Health Month and National Minority Cancer Awareness Month, a time to reflect and shine a light on the disparities that minority populations face in cancer care.
Moving Toward a Better Understanding of the Chronic Lymphocytic Leukemia Patient Experience
CLL Monthly MinutesLeukemia
A new model of the symptoms and impacts faced by patients may lead to better clinical tools for understanding the patient experience.
Watchful Waiting with Chronic Lymphocytic Leukemia
CLL Monthly MinutesLeukemia
Patients who are in a period of active observation should feel comfortable sharing anything that seems abnormal with their healthcare provider.
The Impact of Comorbid Health Conditions on Survival in Chronic Lymphocytic Leukemia
CLL Monthly MinutesLeukemia
A greater number of comorbidities alone may not be sufficient to predict patient survival; age and stage at diagnosis must be considered as well.
Acalabrutinib Shown to Be as Effective as Ibrutinib in Chronic Lymphocytic Leukemia with Less Atrial Fibrillation
CLL Monthly MinutesLeukemia
The first phase 3 trial comparing these drugs shows that acalabrutinib has similar efficacy as ibrutinib with a lower risk of a worrisome side effect.
CONQUER: the patient voice Celebrates Social Workers Everywhere
Social workers serve as “dot connectors” to help patients with cancer overcome barriers. Today, on World Social Work Day, CONQUER magazine celebrates social workers everywhere.
Page 3 of 20
Results 21 - 30 of 192

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country
Gender
Race or Ethnicity
Profession or Role
Primary Interest